Published in Cancer Vaccine Week, September 5th, 2005
According to a study from England, "Immunotherapy of cancer is now entering its second century. Much of our understanding of the complex interaction between tumors and the host immune system has come about because of technological and immunobiological advances in very recent years."
"For some malignancies, such as bladder cancer and malignant melanoma, immunotherapy is becoming an accepted form of adjuvant therapy," said A. McKechnie and colleagues at the University of Nottingham. "However, for most types of cancer,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Vaccine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.